Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies

"Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies." Platelets, 33(8), pp. 1312–1313

Acknowledgements

H. Al-Samkari is the recipient of the American Society of Hematology Scholar Award.

Disclosure statement

Al-Samkari: Consultancy (Agios, Dova/Sobi, Novartis, Rigel, argenx, Forma, Moderna), Research Funding (Agios, Dova/Sobi, Amgen).

Authorship contributions

A. Z. Cheloff contributed to data collection, data analysis, writing of the first draft of the manuscript, critical revisions of the intellectual content and final approval. H. Al-Samkari contributed to concept and design, data collection, data analysis, critical revisions of the intellectual content and final approval.

Additional information

Funding

The authors reported there is no funding associated with the work featured in this article.